OTC monograph publication targets
This article was originally published in The Rose Sheet
Executive Summary
Notice of proposed rulemaking for UVA/UVB sunscreen products targeted for June 2002, FDA announces in unified agenda published in Federal Register Dec. 3. Estimated timeframe marks extension of previous September 2001 date, reflecting tentative nature of dates in biannual publication. Final action on healthcare antiseptic products expected by December 2002, rather than previous year-end 2001 goal. Possible near-term actions include release of skin protectants final monograph (listed as November 2001). Reproposal of skin bleaching products monograph expected by January 2003...
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.